Investigational and not approved by the FDA. This page is educational information only. It is not medical advice and not a recommendation to use anything.

IndexedBuilt automatically from public databases on 2026-09-30. Not yet hand-reviewed by PLOBT.How this works →

Cibinetide

Investigational

Erythropoietin-derived tissue-protective peptide

Also known as: ARA-290, ARA 290, ARA290, PHBSP, PH-BSP, pHBSP peptide, Cibinetida

Evidence score

56/ 100

Moderate evidence

A real evidence base, with gaps

Regulatory standing. In clinical trials, not yet approved
Limited human data. Some human data exists, not conclusive
Registered human trials. 4 registered studies on ClinicalTrials.gov, most advanced Phase 2
1 cited source. Includes primary / regulatory sources

Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.

What it is

Cibinetide, also called ARA-290, is a small synthetic peptide modeled on a region of erythropoietin (EPO). It is designed to engage the so-called innate repair receptor, thought to be a complex of the EPO receptor and the beta common receptor, with the aim of reducing inflammation and supporting tissue repair without stimulating red blood cell production.

What the evidence shows

Automatic summaryLimited human data

Cibinetide is investigational and not FDA-approved. A small number of registered human trials, reaching Phase 2, have explored it mainly for neuropathic pain and small fiber neuropathy, for example in sarcoidosis and diabetes, but these studies were small and do not establish that it works.

Key facts

Molecular formula

C51H84N16O21

Molecular weight

1257.3 g/mol

Registered human trials

Live from ClinicalTrials.gov, refreshed daily.

4registered studies

Phase 2most advanced phase

2completed (sample)

0recruiting (sample)

Cognitive and Neural Effects of ARA290

Phase 2CompletedNCT02070783

Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis

Phase 2CompletedNCT02039687

ARA290 in T2D (Effects of ARA 290, an Erythropoietin Analogue) in Prediabetes and Type 2 Diabetes)

Phase 2UnknownNCT01933529

The Use of ARA290 for the Treatment of Diabetic Macular Oedema

Phase 2TerminatedNCT06626971

Published literature

Live from Europe PMC. This is how much has been published, not how much is proven in humans.

14papers referencing Cibinetide

Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain.

Invest Ophthalmol Vis Sci2017

Corneal nerve fiber size adds utility to the diagnosis and assessment of therapeutic response in patients with small fiber neuropathy.

Sci Rep2018

Cibinetide dampens innate immune cell functions thus ameliorating the course of experimental colitis.

Sci Rep2017

The vasoreparative potential of endothelial colony-forming cells in the ischemic retina is enhanced by cibinetide, a non-hematopoietic erythropoietin mimetic.

Exp Eye Res2019

Sources

Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.